Trials / Completed
CompletedNCT01338805
Phase II BGG492 Capsule Extension for Partial Epilepsy
A Multicenter, Open-label, Follow-up Study to Evaluate the Long-term Safety and Tolerability of BGG492 TID as Adjunctive Therapy in Patients With Partial Onset Seizures Completing Double-blind, Placebo-controlled Study CBGG492A2207 or CBGG492A2211
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 66 Years
- Healthy volunteers
- Not accepted
Summary
This long-term extension study will assess the safety, tolerability and efficacy of BGG492 as adjunctive treatment in patients with partial onset seizures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGG492 |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2012-07-01
- Completion
- 2012-07-01
- First posted
- 2011-04-20
- Last updated
- 2021-03-05
Locations
16 sites across 6 countries: United States, Germany, Hungary, Poland, Slovakia, South Korea
Source: ClinicalTrials.gov record NCT01338805. Inclusion in this directory is not an endorsement.